Brendon Stiles: Neoadjuvant chemo-ICI in marginally resectable patients

Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System, shared on X:

“Love this approach – ‘Trailblazer’ in Cancer Cell. Neoadjuvant chemo-ICI in marginally resectable patients. Led to 25% resection rate and good EFS/OS in both arms. Surgery and RT both safe. Shouldn’t we consider giving our best therapy up front?

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial

Autors: Qing Zhou, Yi Pan, Xuening Yang, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Li Song, Wei Shi, Yi-Long Wu 

‘SHR-1701 is a bifunctional agent composed of an IgG4 monoclonal antibody targeting PD-L1 fused with extracellular domain of the TGF-bII receptor.’

Not suggesting surgery was ‘better here – obviously patients with better clinical response were selected for surgery. They may have done just as well with RT. But I like the paradigm of deciding after induction therapy. I also think it is an easier message for patients.

We are excited to open MDT Bridge at Montefiore Health System, Albert Einstein College of Medicine and see how this works in our own patient population.

Source: Brendon Stiles/X